David P Nicolau (D P Nicolau)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 51

Top Topics

Pseudomonas Aeruginosa

Cystic Fibrosis

Top Venues

Antimicrobial agents and chemotherapy

Journal of clinical microbiology

The Journal of antimicrobial chemotherapy

Microbiology spectrum

This page only lists publications with an associated author ORCID identifier.

Publications

Andrew J Fratoni, Matthew L Gethers, David P Nicolau, Joseph L Kuti
Non-KPC Attributes of Newer β-lactam/β-lactamase Inhibitors, Part 1: Enterobacterales and Pseudomonas aeruginosa. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 79 (1) (2024)
Aliaa Fouad, Patricia J Simner, David P Nicolau, Tomefa E Asempa
Comparison of BD Phoenix and disk diffusion to broth microdilution for determining cefepime susceptibility among carbapenem-resistant Enterobacterales. Journal of clinical microbiology (2024)
Aliaa Fouad, Patricia J Simner, David P Nicolau, Tomefa E Asempa
Comparison of BD Phoenix and disk diffusion to broth microdilution for determining cefepime susceptibility among carbapenem-resistant Enterobacterales. Journal of clinical microbiology 62 (6) (2024)
Aliaa Fouad, Patricia J Simner, David P Nicolau, Tomefa E Asempa
Comparison of BD Phoenix and disk diffusion to broth microdilution for determining cefepime susceptibility among carbapenem-resistant Enterobacterales. Journal of clinical microbiology 62 (6) (2024)
Andrew J Fratoni, Abigail K Kois, Jason A Gluck, David P Nicolau, Joseph L Kuti
Imipenem/relebactam pharmacokinetics in critically ill patients supported on extracorporeal membrane oxygenation. The Journal of antimicrobial chemotherapy (2024)
Yasmeen Abouelhassan, Joseph L Kuti, David P Nicolau, Kamilia Abdelraouf
Ampicillin-sulbactam against Acinetobacter baumannii infections: pharmacokinetic/pharmacodynamic appraisal of current susceptibility breakpoints and dosing recommendations. The Journal of antimicrobial chemotherapy (2024)
Yasmeen Abouelhassan, Joseph L Kuti, David P Nicolau, Kamilia Abdelraouf
Ampicillin-sulbactam against Acinetobacter baumannii infections: pharmacokinetic/pharmacodynamic appraisal of current susceptibility breakpoints and dosing recommendations. The Journal of antimicrobial chemotherapy 79 (9) (2024)
Andrew J Fratoni, Matthew L Gethers, David P Nicolau, Joseph L Kuti
Non-KPC Attributes of Newer β-lactam/β-lactamase Inhibitors, Part 1: Enterobacterales and Pseudomonas aeruginosa. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 79 (1) (2024)
Aliaa Fouad, Patricia J Simner, David P Nicolau, Tomefa E Asempa
Comparison of BD Phoenix and disk diffusion to broth microdilution for determining cefepime susceptibility among carbapenem-resistant Enterobacterales. Journal of clinical microbiology 62 (6) (2024)
Andrew J Fratoni, Abigail K Kois, Jason A Gluck, David P Nicolau, Joseph L Kuti
Imipenem/relebactam pharmacokinetics in critically ill patients supported on extracorporeal membrane oxygenation. The Journal of antimicrobial chemotherapy 79 (5) (2024)
Andrew J Fratoni, Abigail K Kois, Jason A Gluck, David P Nicolau, Joseph L Kuti
Imipenem/relebactam pharmacokinetics in critically ill patients supported on extracorporeal membrane oxygenation. The Journal of antimicrobial chemotherapy 79 (5) (2024)
Kamilia Abdelraouf, David P Nicolau
In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model. The Journal of antimicrobial chemotherapy (2023)
Andrew J Fratoni, Amity L Roberts, David P Nicolau, Joseph L Kuti
Effects of clinically achievable pulmonary antibiotic concentrations on the recovery of bacteria: in vitro comparison of the BioFire FILMARRAY Pneumonia Panel versus conventional culture methods in bronchoalveolar lavage fluid. Journal of clinical microbiology (2023)
Victor H Ruiz, Andrew Fratoni, David P Nicolau, Joseph L Kuti
In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis. Antimicrobial agents and chemotherapy (2023)
Andrew J Fratoni, Amity L Roberts, David P Nicolau, Joseph L Kuti
Effects of clinically achievable pulmonary antibiotic concentrations on the recovery of bacteria: in vitro comparison of the BioFire FILMARRAY Pneumonia Panel versus conventional culture methods in bronchoalveolar lavage fluid. Journal of clinical microbiology 62 (1) (2023)
Yasmeen Abouelhassan, Christian M Gill, David P Nicolau
Assessing the in vivo efficacy of rational antibiotics and combinations against difficult-to-treat Pseudomonas aeruginosa producing GES β-lactamases. The Journal of antimicrobial chemotherapy (2023)
Jason Alexander Roberts, David P Nicolau, Ignacio Martin-Loeches, C Andrew Deryke, Maria C Losada, Jiejun Du, Munjal Patel, Matthew L Rizk, Amanda Paschke, Luke F Chen
Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance. JAC-antimicrobial resistance 5 (2) (2023)
Andrew J Fratoni, Amity L Roberts, David P Nicolau, Joseph L Kuti
Effects of clinically achievable pulmonary antibiotic concentrations on the recovery of bacteria: in vitro comparison of the BioFire FILMARRAY Pneumonia Panel versus conventional culture methods in bronchoalveolar lavage fluid. Journal of clinical microbiology 62 (1) (2023)
Christian M Gill, David P Nicolau
In Vivo Pharmacodynamic Profile of EVER206, a Novel Polymyxin Antimicrobial, against Gram-Negative Bacteria in the Murine Thigh Infection Model. Antimicrobial agents and chemotherapy (2023)
Tomefa E Asempa, Joseph L Kuti, Jeffrey C Nascimento, Samuel J Pope, Edward L Salerno, Patrick J Troy, David P Nicolau
Bronchopulmonary disposition of IV cefepime/taniborbactam (2-0.5 g) administered over 2 h in healthy adult subjects. The Journal of antimicrobial chemotherapy (2023)
Andrew J Fratoni, Amity L Roberts, David P Nicolau, Joseph L Kuti
Effects of clinically achievable pulmonary antibiotic concentrations on the recovery of bacteria: in vitro comparison of the BioFire FILMARRAY Pneumonia Panel versus conventional culture methods in bronchoalveolar lavage fluid. Journal of clinical microbiology 62 (1) (2023)
Su Young Lee, Christian M Gill, David P Nicolau, null null
Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa. The Journal of antimicrobial chemotherapy (2023)
Andrew J Fratoni, Amity L Roberts, David P Nicolau, Joseph L Kuti
Effects of clinically achievable pulmonary antibiotic concentrations on the recovery of bacteria: in vitro comparison of the BioFire FILMARRAY Pneumonia Panel versus conventional culture methods in bronchoalveolar lavage fluid. Journal of clinical microbiology 62 (1) (2023)
Tomefa E Asempa, Abigail K Kois, Christian M Gill, David P Nicolau
Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48. The Journal of antimicrobial chemotherapy (2023)
Andrew J Fratoni, Amity L Roberts, David P Nicolau, Joseph L Kuti
Effects of clinically achievable pulmonary antibiotic concentrations on the recovery of bacteria: in vitro comparison of the BioFire FILMARRAY Pneumonia Panel versus conventional culture methods in bronchoalveolar lavage fluid. Journal of clinical microbiology 62 (1) (2023)
Andrew J Fratoni, Amity L Roberts, David P Nicolau, Joseph L Kuti
Effects of clinically achievable pulmonary antibiotic concentrations on the recovery of bacteria: in vitro comparison of the BioFire FILMARRAY Pneumonia Panel versus conventional culture methods in bronchoalveolar lavage fluid. Journal of clinical microbiology 62 (1) (2023)
Andrew J Fratoni, Amity L Roberts, David P Nicolau, Joseph L Kuti
Effects of clinically achievable pulmonary antibiotic concentrations on the recovery of bacteria: in vitro comparison of the BioFire FILMARRAY Pneumonia Panel versus conventional culture methods in bronchoalveolar lavage fluid. Journal of clinical microbiology 62 (1) (2023)
Jason Alexander Roberts, David P Nicolau, Ignacio Martin-Loeches, C Andrew Deryke, Maria C Losada, Jiejun Du, Munjal Patel, Matthew L Rizk, Amanda Paschke, Luke F Chen
Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance. JAC-antimicrobial resistance 5 (2) (2023)
Christian M Gill, David P Nicolau, null null
Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa. The Journal of antimicrobial chemotherapy (2022)
Tomefa E Asempa, Christian M Gill, Vindana Chibabhai, David P Nicolau
Comparison of Zinc Concentrations in the Broth of Commercial Automated Susceptibility Testing Devices (Vitek 2, MicroScan, BD Phoenix, and Sensititre). Microbiology spectrum 10 (2) (2022)
Maxwell J Lasko, Matthew L Gethers, Jennifer L Tabor-Rennie, David P Nicolau, Joseph L Kuti
In Vitro Time-Kill Studies of Trimethoprim/Sulfamethoxazole against Stenotrophomonas maltophilia versus Escherichia coli Using Cation-Adjusted Mueller-Hinton Broth and ISO-Sensitest Broth. Antimicrobial agents and chemotherapy 66 (3) (2022)
Yasmeen Abouelhassan, Andrew J Fratoni, Ashley K Shepard, David P Nicolau, Tomefa E Asempa
Pharmacokinetics and soft-tissue distribution of tebipenem pivoxil hydrobromide using microdialysis: a study in healthy subjects and patients with diabetic foot infections. The Journal of antimicrobial chemotherapy (2022)
Ana Motos, Gianluigi Li Bassi, Francesco Pagliara, Laia Fernandez-Barat, Hua Yang, Eli Aguilera Xiol, Tarek Senussi, Francesco A Idone, Chiara Travierso, Chiara Chiurazzi, Rosanel Amaro, Minlan Yang, Joaquim Bobi, Montserrat Rigol, David P Nicolau, Gerard Frigola, Roberto Cabrera, Jose Ramirez, Paolo Pelosi, Francesco Blasi, Massimo Antonelli, Antonio Artigas, Jordi Vila, Marin Kollef, Antoní Torres
Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia. Antimicrobial agents and chemotherapy 65 (2) (2021)
Andrew J Fratoni, David P Nicolau, Joseph L Kuti
A guide to therapeutic drug monitoring of β-lactam antibiotics. Pharmacotherapy 41 (2) (2021)
Tomefa E Asempa, Hannah Bajor, Jessica H Mullins, Janice Hartnett, David P Nicolau
Evaluation of Metallo-β-Lactamase Susceptibility Testing in a Physiologic Medium. Microbiology spectrum (2021)
Vidmantas Petraitis, Povilas Kavaliauskas, Povilas Kavaliauskas, Ethan Naing, Andrew Garcia, Christina Sutherland, Aki Yoneda Kau, Nicholas Goldner, Christopher Bulow, David P Nicolau, Thomas J Walsh
Pharmacokinetics, Tissue Distribution, and Efficacy of VIO-001 (Meropenem/Piperacillin/Tazobactam) for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia in Immunocompetent Rabbits with Chronic Indwelling Vascular Catheters. Antimicrobial agents and chemotherapy 65 (11) (2021)
Maxwell J Lasko, Gabriel T Cuba, Carlos R V Kiffer, David P Nicolau
Evaluation of high-concentration EDTA-modified carbapenemase inactivation method (eCIM) for SPM-producing Pseudomonas aeruginosa. Archives of microbiology 204 (1) (2021)
Alison L Blackman, Praneeth Jarugula, David P Nicolau, Sai Ho Chui, Manjari Joshi, Emily L Heil, Mathangi Gopalakrishnan
Evaluation of Linezolid Pharmacokinetics in Critically Ill Obese Patients with Severe Skin and Soft Tissue Infections. Antimicrobial agents and chemotherapy 65 (2) (2021)
Jared L Crandon, Joseph L Kuti, David P Nicolau
Erratum for Crandon et al., "Comparative Efficacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia Model". Antimicrobial agents and chemotherapy 65 (12) (2021)
Tomefa E Asempa, Kamilia Abdelraouf, David P Nicolau
The Ongoing Challenge with NDM-Harboring Enterobacteriaceae in Murine Infection Models. Antimicrobial agents and chemotherapy 65 (2) (2021)
Christian M Gill, Elif Aktaş, Wadha Alfouzan, Lori Bourassa, Adrian Brink, Carey-Ann D Burnham, Rafael Cantón, Yehuda Carmeli, Marco Falcone, Carlos Kiffer, Anna Marchese, Octavio Martinez, Spyros Pournaras, Harald Seifert, Abrar K Thabit, Maria Virginia Villegas, Lars F Westblade, David P Nicolau, null null
Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization. Antimicrobial agents and chemotherapy 65 (11) (2021)
Christian M Gill, Adrian Brink, Chun Yat Chu, Jennifer Coetzee, George Dimopoulos, Clinton Moodley, Christoffel Johannes Opperman, Spyros Pournaras, Fred C Tenover, Isabella A Tickler, Hafsah Deepa Tootla, Sophia Vourli, David P Nicolau
Phenotypic/Genotypic Profile of OXA-10-Like-Harboring, Carbapenem-Resistant Pseudomonas aeruginosa: Using Validated Pharmacokinetic/Pharmacodynamic In Vivo Models To Further Evaluate Enzyme Functionality and Clinical Implications. Antimicrobial agents and chemotherapy 65 (10) (2021)
Maxwell J Lasko, Kamilia Abdelraouf, David P Nicolau
In Vivo Activity of WCK 4282 (High-Dose Cefepime/Tazobactam) against Serine-β-Lactamase-Producing Enterobacterales and Pseudomonas aeruginosa in the Neutropenic Murine Lung Infection Model. Antimicrobial agents and chemotherapy 65 (4) (2021)
Tomefa E Asempa, Kamilia Abdelraouf, David P Nicolau
Activity of β-Lactam Antibiotics against Metallo-β-Lactamase-Producing Enterobacterales in Animal Infection Models: a Current State of Affairs. Antimicrobial agents and chemotherapy 65 (6) (2021)
Maxwell J Lasko, Allison M Conelius, Oscar K Serrano, David P Nicolau, Joseph L Kuti
Impact of Intraoperative Cell Salvage on Concentrations of Antibiotics Used for Surgical Prophylaxis. Antimicrobial agents and chemotherapy 64 (12) (2020)
D Battaglini, A Motos, G Li Bassi, H Yang, F Pagliara, M Yang, E Aguilera Xiol, A Meli, J Bobi, G Frigola, T Senussi, F Idone, C Travierso, C Chiurazzi, L Fernandez-Barat, M Rigol, J Ramirez, P Pelosi, D Chiumello, M Antonelli, David P Nicolau, J Bringue, A Artigas, L Guerrero, D Soy, Antoní Torres
Efficacy of Telavancin in Comparison to Linezolid in a Porcine Model of Severe Methicillin-Resistant Staphylococcus aureus Pneumonia. Antimicrobial agents and chemotherapy 65 (1) (2020)
Tomefa E Asempa, Sergey Izmailyan, Kenneth Lawrence, David P Nicolau
Efficacy and Safety of Eravacycline in Obese Patients: A Post Hoc Analysis of Pooled Data From the IGNITE1 and IGNITE4 Clinical Trials. Open forum infectious diseases 7 (12) (2020)
Anastasia Bilinskaya, Douglas J Buckheit, Michael Gnoinski, Tomefa E Asempa, David P Nicolau
Variability in Zinc Concentration among Mueller-Hinton Broth Brands: Impact on Antimicrobial Susceptibility Testing of Metallo-β-Lactamase-Producing Enterobacteriaceae. Journal of clinical microbiology 58 (12) (2020)
Maxwell J Lasko, Christian M Gill, Tomefa E Asempa, David P Nicolau
EDTA-modified carbapenem inactivation method (eCIM) for detecting IMP Metallo-β-lactamase-producing Pseudomonas aeruginosa: an assessment of increasing EDTA concentrations. BMC microbiology 20 (1) (2020)
Christian M Gill, Tomefa E Asempa, Isabella A Tickler, Caitlin Dela Cruz, Fred C Tenover, David P Nicolau
Evaluation of the Xpert Carba-R NxG Assay for Detection of Carbapenemase Genes in a Global Challenge Set of Pseudomonas aeruginosa Isolates. Journal of clinical microbiology 58 (12) (2020)
Iris H Chen, David P Nicolau, Joseph L Kuti
Imipenem/Cilastatin/Relebactam Alone and in Combination against Pseudomonas aeruginosa in the In Vitro Pharmacodynamic Model. Antimicrobial agents and chemotherapy 64 (12) (2020)